Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.
Managed care organizations are looking for new skills in healthcare leaders (and in some cases hiring for completely new leadership roles). Here are four emerging trends to watch.
A Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.
In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.
The high cost of specialty drugs continues to plague the healthcare industry. Here’s why.
Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.